Therapeutic and diagnostic targeting of fibrosis in metabolic, proliferative and viral disorders

Adv Drug Deliv Rev. 2021 Aug:175:113831. doi: 10.1016/j.addr.2021.113831. Epub 2021 Jun 15.

Abstract

Fibrosis is a common denominator in many pathologies and crucially affects disease progression, drug delivery efficiency and therapy outcome. We here summarize therapeutic and diagnostic strategies for fibrosis targeting in atherosclerosis and cardiac disease, cancer, diabetes, liver diseases and viral infections. We address various anti-fibrotic targets, ranging from cells and genes to metabolites and proteins, primarily focusing on fibrosis-promoting features that are conserved among the different diseases. We discuss how anti-fibrotic therapies have progressed over the years, and how nanomedicine formulations can potentiate anti-fibrotic treatment efficacy. From a diagnostic point of view, we discuss how medical imaging can be employed to facilitate the diagnosis, staging and treatment monitoring of fibrotic disorders. Altogether, this comprehensive overview serves as a basis for developing individualized and improved treatment strategies for patients suffering from fibrosis-associated pathologies.

Keywords: Atherosclerosis; Cancer; Cardiovascular disease; Diabetes; Drug targeting; Fibrosis; Imaging; Liver; Nanomedicine; Viral infection.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Fibrosis / diagnosis
  • Fibrosis / drug therapy*
  • Humans
  • Metabolic Diseases / diagnosis
  • Metabolic Diseases / drug therapy
  • Metabolic Diseases / pathology*
  • Neoplasms / diagnosis
  • Neoplasms / drug therapy
  • Neoplasms / pathology*
  • Virus Diseases / diagnosis
  • Virus Diseases / drug therapy
  • Virus Diseases / pathology*